Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 05, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 850,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,400.9 pence per share.
- Treasury Holdings: 248,922,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,749,188,255 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 850,000 shares on February 05, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (248,922,678) against subsequent filings to track ongoing buyback activity.
- Confirm the total voting rights denominator (5,749,188,255) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share repurchase authority utilized.